Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management

Cancer

Volumn 110, Issue 1, 2007, Pages 1-12

  Bichakjian, Christopher K ^a   Lowe, Lori ^a   Lao, Christopher D ^b   Sandler, Howard M ^a   Bradford, Carol R ^a   Johnson, Timothy M ^a   Wong, Sandra L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Histopathologic profile; Literature review; Merkel cell carcinoma; Multidisciplinary management; Sentinel lymph node biopsy

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CARBOPLATIN; CISPLATIN; CYTOKERATIN 20; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FARNESYLTHIOSALICYLIC ACID; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IRINOTECAN; MELPHALAN; PROTEIN BCL 2; PROTEIN P53; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ALGORITHM; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYST; DIFFERENTIAL DIAGNOSIS; EXCISION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIPOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; MERKEL CELL; MERKEL CELL TUMOR; MONOTHERAPY; ONCOGENE H RAS; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PYOGENIC GRANULOMA; REVIEW; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SKIN LYMPHOMA; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ALGORITHMS; CARCINOMA, MERKEL CELL; COMBINED MODALITY THERAPY; HUMANS; INTERDISCIPLINARY COMMUNICATION; PRACTICE GUIDELINES; SENTINEL LYMPH NODE BIOPSY; SKIN; SKIN NEOPLASMS;

EID: 34250821065     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22765     Document Type: Review

References (101)

1. U.S. Bureau of the Census. Dramatic changes in U.S. aging highlighted in new census, NIH report. US Census Bureau [monograph online]. March 9, 2006. Available at: http://www.census.gov/press-release/www/releases/archives/ aging_population/006544.html Accessed January 19, 2007.
2. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89:1-4.
3. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300-2309.
4. Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001;8:204-208.
5. Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. 1999;8:153-158.
6. Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med. 1998;339:1247-1248.
7. Hattori H. Merkel cell carcinoma composed of small, intermediate and squamous cell foci showing mutually exclusive expression of neuroendocrine markers and cytokeratin 20. Br J Dermatol. 2003;148:183-185.
8. Penn I, First MR. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation. 1999;68:1717-1721.
9. Buell JF, Trofe J, Hanaway MJ, et al. Immunosuppression and Merkel cell cancer. Transplant Proc. 2002;34:1780-1781.
10. Robak E, Biernat W, Krykowski E, Jeziorski A, Robak T. Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. Leuk Lymphoma. 2005;46:909-914.
11. Takabayashi M, Sakai R, Sakamoto H, et al. Merkel cell carcinoma developing after antithymocyte globulin and cyclosporine therapy for aplastic anemia. Anticancer Drugs. 2003;14:251-253.
12. Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet. 2002;359:497-498.
13. Vlad R, Woodlock TJ. Merkel cell carcinoma after chronic lymphocytic leukemia: case report and literature review. Am J Clin Oncol. 2003;26:531-534.
14. Ho SY, Tsai YC, Lee MC, Guo HR. Merkel cell carcinoma in patients with long-term ingestion of arsenic. J Occup Health. 2005;47:188-192.
15. Van Gele M, Leonard JH, Van Roy N, et al. Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma. Int J Cancer. 2002;101:137-145.
16. Leonard JH, Cook AL, Nancarrow D, et al. Deletion mapping on the short arm of chromosome 1 in Merkel cell carcinoma. Cancer Detect Prev. 2000;24:620-627.
17. Jansen B, Heere-Ress E, Schlagbauer-Wadl H, et al. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med. 1999;77:792-797.
18. Kennedy MM, Blessing K, King G, Kerr KM. Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol. 1996;18:273-277.
19. Schlagbauer-Wadl H, Klosner G, Heere-Ress E, et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol. 2000;114:725-730.
20. Houben R, Michel B, Vetter-Kauczok CS, et al. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol. 2006;126:1135-1142.
21. Merkel F. Tastzellen und Tastkorperchen bei den Haustieren und beim Menschen. Arch Mikrosk Anat. 1875;11:636-652.
22. Halata Z, Grim M, Bauman KI. Friedrich Sigmund Merkel and his "Merkel cell", morphology, development, and physiology: review and new results. Anat Rec A Discov Mol Cell Evol Biol. 2003;271:225-239.
23. Szeder V, Grim M, Halata Z, Sieber-Blum M. Neural crest origin of mammalian Merkel cells. Dev Biol. 2003;253:258-263.
24. Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972;105:107-110.
25. Tang CK, Toker C. Trabecular carcinoma of the skin: an ultrastructural study. Cancer. 1978;42:2311-2321.
26. Ferringer T, Rogers HC, Metcalf JS. Merkel cell carcinoma in situ. J Cutan Pathol. 2005;32:162-165.
27. Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J Clin Oncol. 2002;20:588-598.
28. Chen KT. Merkel's cell (neuroendocrine) carcinoma of the vulva. Cancer. 1994;73:2186-2191.
29. Yom SS, Rosenthal DI, El-Naggar AK, Kies MS, Hessel AC. Merkel cell carcinoma of the tongue and head and neck oral mucosal sites. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:761-768.
30. Eng TY, Boersma MG, Fuller CD, Cavanaugh SX, Valenzuela F, Herman TS. Treatment of Merkel cell carcinoma. Am J Clin Oncol. 2004;27:510-515.
31. Muller A, Keus R, Neumann N, Lammering G, Schnabel T. Management of Merkel cell carcinoma: case series of 36 patients. Oncol Rep. 2003;10:577-585.
32. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer. 1999;85:2589-2595.
33. Bachmann J, Kleeff J, Bergmann F, et al. Pancreatic metastasis of Merkel cell carcinoma and concomitant insulinoma: case report and literature review. World J Surg Oncol. 2005;3:58.
34. Giraldez Rodriguez LA, Giraldez Casasnovas LJ, Ramos E. Merkel cell carcinoma of the cheek with metastases to the parotid gland: a report of two cases. Bol Assoc Med PR. 2004;96:6-10.
35. Idowu MO, Contos M, Gill S, Powers C. Merkel cell carcinoma: a report of gastrointestinal metastasis and review of the literature. Arch Pathol Lab Med. 2003;127:367-369.
36. Jongbloed MR, Kanen BL, Visser M, Niessen H, Flens MJ, Loffeld RJ. Case 2. Intracardiac metastasis from a Merkel cell carcinoma. J Clin Oncol. 2004;22:1153-1156.
37. Mack DP, Moussa M, Cook A, Izawa JI. Metastatic Merkel cell tumor to the prostate and bladder. Urology. 2004;64:156-158.
38. Payne MM, Rader AE, McCarthy DM, Rodgers WH. Merkel cell carcinoma in a malignant pleural effusion: case report. [serial online] Cytojournal. 2004;1:5.
39. Tam CS, Turner P, McLean C, Whitehead S, Cole-Sinclair M. 'Leukaemic' presentation of metastatic Merkel cell carcinoma [letter]. Br J Haematol. 2005;129:446.
40. Tummala MK, Hausner PF, McGuire WP, Gipson T, Berkman A. Case 1. Testis: a sanctuary site in Merkel cell carcinoma. J Clin Oncol. 2006;24:1008-1009.
41. Veness MJ, Perera L, McCourt J, et al. Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. Aust N Z J Surg. 2005;75:275-281.
42. Junquera L, Torre A, Vicente JC, Garcia-Consuegra L, Fresno MF. Complete spontaneous regression of Merkel cell carcinoma. Ann Otol Rhinol Laryngol. 2005;114:376-380.
43. Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17:201-209.
44. Sais G, Admella C, Soler T. Spontaneous regression in primary cutaneous neuroendocrine (Merkel cell) carcinoma: a rare immune phenomenon? J Eur Acad Dermatol Venereol. 2002;16:82-83.
45. Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol. 1997;37(5 pt 1):734-739.
46. Mott RT, Smoller BR, Morgan MB. Merkel cell carcinoma: a clinicopathologic study with prognostic implications. J Cutan Pathol. 2004;31:217-223.
47. Ratner D, Nelson BR, Brown MD, Johnson TM. Merkel cell carcinoma. J Am Acad Dermatol. 1993;29(2 pt 1):143-156.
48. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS. Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol. 2006;28:99-104.
49. Hanly AJ, Elgart GW, Jorda M, Smith J, Nadji M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol. 2000;27:118-120.
50. Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001;125:228-231.
51. Acebo E, Vidaurrazaga N, Varas C, Burgos-Bretones JJ, Diaz-Perez JL. Merkel cell carcinoma: a clinicopathological study of 11 cases. J Eur Acad Dermatol Venereol. 2005;19:546-551.
52. Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R. CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol. 2002;24:289-293.
53. Allen PJ, Zhang ZF, Coit DG. Surgical management of Merkel cell carcinoma. Ann Surg. 1999;229:97-105.
54. Ott MJ, Tanabe KK, Gadd MA, et al. Multimodality management of Merkel cell carcinoma. Arch Surg. 1999;134:388-392; discussion, 392-383.
55. Lewis KG, Weinstock MA, Weaver AL, Otley CC. Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol. 2006;142:693-700.
56. Morrison WH, Peters LJ, Silva EG, Wendt CD, Ang KK, Goepfert H. The essential role of radiation therapy in securing locoregional control of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys. 1990;19:583-591.
57. Pacella J, Ashby M, Ainslie J, Minty C. The role of radiotherapy in the management of primary cutaneous neuroendocrine tumors (Merkel cell or trabecular carcinoma): experience at the Peter MacCallum Cancer Institute (Melbourne, Australia). Int J Radiat Oncol Biol Phys. 1988;14:1077-1084.
58. Wong KC, Zuletta F, Clarke SJ, Kennedy PJ. Clinical management and treatment outcomes of Merkel cell carcinoma. Aust NZ J Surg. 1998;68:354-358.
59. Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C, Knapper WK. Merkel cell carcinoma. Prognosis and management. Arch Surg. 1991;126:1514-1519.
60. McAfee WJ, Morris CG, Mendenhall CM, Werning JW, Mendenhall NP, Mendenhall WM. Merkel cell carcinoma: treatment and outcomes. Cancer. 2005;104:1761-1764.
61. Gillenwater AM, Hessel AC, Morrison WH, et al. Merkel cell carcinoma of the head and neck: effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg. 2001;127:149-154.
62. Eng TY, Naguib M, Fuller CD, Jones WE 3rd, Herman TS. Treatment of recurrent Merkel cell carcinoma: an analysis of 46 cases. Am J Clin Oncol. 2004;27:576-583.
63. Anderson SE, Beer KT, Banic A, et al. MRI of Merkel cell carcinoma: histologic correlation and review of the literature. AJR Am J Roentgenol. 2005;185:1441-1448.
64. Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM. Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol. 2005;28:205-210.
65. Johnson TM, Bradford CR, Gruber SB, Sondak VK, Schwartz JL. Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol. 2004;140:107-113.
66. Gupta SG, Wang LC, Penas PF, Gellenthin M, Lee SJ, Nghiem P. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: the Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. 2006;142:685-690.
67. Koljonen V, Haglund C, Tukiainen E, Bohling T. Neuroendocrine differentiation in primary Merkel cell carcinoma - possible prognostic significance. Anticancer Res. 2005;25:853-858.
68. Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Bohling T. Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol. 2005;58:297-300.
69. Llombart B, Monteagudo C, Lopez-Guerrero JA, et al. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology. 2005;46:622-634.
70. Andea A, Coit DC, Busam K. An analysis of morphologic parameters as prognostic markers in Merkel cell carcinoma. Am J Dermatopathol. 2006;28:228.
71. Sandel HD 4th, Day T, Richardson MS, Scarlett M, Gutman KA. Merkel cell carcinoma: does tumor size or depth of invasion correlate with recurrence, metastasis, or patient survival? Laryngoscope. 2006;116:791-795.
72. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
73. Hill AD, Brady MS, Coit DG. Intraoperative lymphatic mapping and sentinel lymph node biopsy for Merkel cell carcinoma. Br J Surg. 1999;86:518-521.
74. Messina JL, Reintgen DS, Cruse CW, et al. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol. 1997;4:389-395.
75. Allen PJ, Busam K, Hill AD, Stojadinovic A, Coit DG. Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma. Cancer. 2001;92:1650-1655.
76. Mehrany K, Otley CC, Weenig RH, Phillips PK, Roenigk RK, Nguyen TH. A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg. 2002;28:113-117; discussion, 117.
77. Johnson TM, Chang A, Redman B, et al. Management of melanoma with a multidisciplinary melanoma clinic model. J Am Acad Dermatol. 2000;42(5 pt 1):820-826.
78. Kokoska ER, Kokoska MS, Collins BT, Stapleton DR, Wade TP. Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg. 1997;174:688-693.
79. O'Connor WJ, Brodland DG. Merkel cell carcinoma. Dermatol Surg. 1996;22:262-267.
80. Shaw JH, Rumball E. Merkel cell tumour: clinical behaviour and treatment. Br J Surg. 1991;78:138-142.
81. Boyer JD, Zitelli JA, Brodland DG, D'Angelo G. Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. J Am Acad Dermatol. 2002;47:885-892.
82. Meeuwissen JA, Bourne RG, Kearsley JH. The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys. 1995;31:325-331.
83. Mortier L, Mirabel X, Fournier C, Piette F, Lartigau E. Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol. 2003;139:1587-1590.
84. Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol. 2004;151:308-319.
85. Uren RF, Howman-Giles R, Thompson JF, et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg. 2000;135:1168-1172.
86. Schmalbach CE, Lowe L, Teknos TN, Johnson TM, Bradford CR. Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. Arch Otolaryngol Head Neck Surg. 2005;131:610-614.
87. King MM, Osswald MB. Adjuvant chemotherapy for Merkel cell carcinoma [comment]. Am J Clin Oncol. 2005;28: 634.
88. Poulsen M, Rischin D, Walpole E, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study - TROG 96:07. J Clin Oncol. 2003;21:4371-4376.
89. Poulsen MG, Rischin D, Porter I, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys. 2006;64:114-119.
90. Gupta AS, Heinzman S, Levine EA. Successful treatment of in-transit metastases from Merkel's cell carcinoma with isolated hyperthermic limb perfusion. South Med J. 1998;91:289-292.
91. Olieman AF, Lienard D, Eggermont AM, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg. 1999;134:303-307.
92. Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000;18:2493-2499.
93. Dirix LY, Prove A, Becquart D, Wouters E, Vermeulen P, Van Oosterom A. Tumor lysis syndrome in a patient with metastatic Merkel cell carcinoma. Cancer. 1991;67:2207-2210.
94. Poulsen M, Rischin D, Walpole E, et al. Analysis of toxicity of Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group study. Int J Radiat Oncol Biol Phys. 2001;51:156-163.
95. O'Brien ME, Borthwick A, Rigg A, et al. Mortality within 30 days of chemotherapy: a clinical governance bench-marking issue for oncology patients. Br J Cancer. 2006;95:1632-1636.
96. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet. 1996;348:563-566.
97. Davis MP, Miller EM, Rau RC, Johnson OE, Naille RA, Crnkovich MJ. The use of VP16 and cisplatin in the treatment of Merkel cell carcinoma. J Dermatol Surg Oncol. 1990;16:276-278.
98. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441-5447.
99. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23:8389-8395.
100. Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res. 2006;26(1B):777-781.
101. Miller SJ, Alam M, Andersen J, et al. Merkel cell carcinoma. J Natl Compr Canc Netw. 2006;4:704-712.